Adult Dosing
Treatment of HIV infection
- 600 mg PO bid
- If nausea occurs, use escalating dose: 300 mg PO bid increased at 2- to 3-day intervals by 100 mg PO bid up to the final dose of 600 mg PO bid
Pediatric Dosing
Treatment of HIV infection
- >1 mo: 350 - 400 mg/m2 PO bid
- To minimize nausea: 250 mg/m2 PO bid initially
- Titrate: May increase by 50 mg/m2 PO bid at 2 to 3 day intervals
- Max: 600 mg PO bid
[Outline]
- Severe, even fatal, side effects may occur because of drug interactions with certain non-sedating antihistamines, sedatives and tranquilizers, antiarrhythmics, heart medicines or ergot-containing medicines [US Black Box Warning]
- Consider drug-drug interaction potential to reduce risk of serious or life-threatening adverse reactions
- Due to possible toxicities, ritonavir oral solution should not be used in preterm neonates in the immediate postnatal period. A safe and effective dose of oral solution in this patient population has not been recognized
- Fatalities like hepatic transaminase elevation shave occurred. Monitor liver function before and during therapy, especially in patients with underlying hepatic disease, including hepatitis B and hepatitis C, or marked transaminase elevations
- Suspend therapy as clinically appropriate if symptoms of pancreatitis occur
- Allergic Reactions/hypersensitivity has been reported with the therapy and includes anaphylaxis, toxic epidermal necrolysis (TEN), Stevens-Johnson Syndrome, urticaria, mild skin eruptions, bronchospasm and angioedema. Discontinue treatment if severe reactions develop
- PR interval prolongation may occur in some patients. Cases of second and third degree heart block have been reported. Use with caution with patients with preexisting conduction system disease, ischemic heart disease, cardiomyopathy, underlying structural heart disease or when administering with other drugs that may prolong the PR interval
- Monitor total cholesterol and triglycerides elevations prior to therapy and periodically thereafter
- Patients may develop new onset or exacerbations of diabetes mellitus, hyperglycemia, immune reconstitution syndrome, autoimmune disorders (eg, Graves' disease, polymyositis, and Guillain-Barre syndrome) in the setting of immune reconstitution, distribution/accumulation of body fat
- Therapy may cause spontaneous bleeding in patients with hemophilia, and additional factor VIII may be required
Caution: Use cautiously in
- Hepatic impairment
- Structural heart disease
- Cardiac conduction disturbances
- Ischemic heart disease
- Cardiomyopathy
- Diabetes mellitus
- Hemophilia
Pregnancy Category:B
Breastfeeding: Unsafe, women with HIV infection should not breastfeed.
Pricing data from www.DrugStore.com in U.S.A.
- Norvir 100 MG CAPS [Bottle] (ABBOTT)
30 mg = $290.98
90 mg = $842.94 - Norvir 100 MG TABS [Bottle] (ABBOTT)
30 mg = $289.99
90 mg = $825.91 - Norvir 80 MG/ML SOLN [Bottle] (ABBOTT)
240 ml = $1508.58
720 ml = $4525.74
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.
Drug Name: Norvir 100 MG Oral Capsule
Ingredient(s): Ritonavir
Imprint: 100;DS
Color(s): White
Shape: Oval
Size (mm): 22.00
Score: 1
Inactive Ingredient(s): butylated hydroxytoluene / alcohol / gelatin / oleic acid / polyoxyl 35 castor oil / titanium dioxide
Drug Label Author:
Abbott Laboratories
DEA Schedule:
Non-Scheduled
Drug Name: Norvir 100 MG Oral Tablet
Ingredient(s): Ritonavir
Imprint: A;NK
Color(s): White
Shape: Oval
Size (mm): 22.00
Score: 1
Inactive Ingredient(s): titanium dioxide / anhydrous dibasic calcium phosphate / sorbitan monolaurate / colloidal silicon dioxide / sodium stearyl fumarate / hypromellose / polyethylene glycol 400 / hydroxypropyl cellulose / talc / polyethylene glycol 3350 / polysorbate 80
Drug Label Author:
Abbott Laboratories
DEA Schedule:
Non-Scheduled
